GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (XBRU:CYAD) » Definitions » 3-Year FCF Growth Rate

Celyad Oncology (XBRU:CYAD) 3-Year FCF Growth Rate : 18.50% (As of Jun. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Celyad Oncology 3-Year FCF Growth Rate?

Celyad Oncology's Free Cash Flow per Share for the three months ended in Jun. 2023 was €0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.50% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 20.50% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 3.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Celyad Oncology was 24.70% per year. The lowest was -32.70% per year. And the median was 7.30% per year.


Competitive Comparison of Celyad Oncology's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Celyad Oncology's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celyad Oncology's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's 3-Year FCF Growth Rate falls into.



Celyad Oncology 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Celyad Oncology  (XBRU:CYAD) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Celyad Oncology 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Celyad Oncology (XBRU:CYAD) Business Description

Traded in Other Exchanges
Address
Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435
Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.

Celyad Oncology (XBRU:CYAD) Headlines

No Headlines